Impact of Maternal and Infant Antiretroviral Drug Regimens on Drug Resistance in HIV-infected Breastfeeding Infants

Pediatric Infectious Disease Journal

Volumn 32, Issue 4, 2013, Pages e164-e169

  Fogel, Jessica M ^a   Mwatha, Anthony ^a   Richardson, Paul ^a   Brown, Elizabeth R ^a   Chipato, Tsungai ^a   Alexandre, Michel ^a   Moodley, Dhayendre ^a   Elbireer, Ali ^a   Mirochnick, Mark ^a   George, Kathleen ^a   Mofenson, Lynne M ^a   Zwerski, Sheryl ^a   Coovadia, Hoosen M ^a   Eshleman, Susan H ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Extended nevirapine; HIV; Nevirapine resistance; Prevention of mother to child transmission

Indexed keywords

EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PLACEBO; STAVUDINE; ZIDOVUDINE;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; BREAST FEEDING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE TRANSMISSION; FEMALE; FISHER EXACT TEST; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; INFECTION RISK; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL;

ANTI-RETROVIRAL AGENTS; BREAST FEEDING; CHEMOPREVENTION; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; MALE; NEVIRAPINE; PLACEBOS; RNA, VIRAL; TANZANIA; TREATMENT OUTCOME; UGANDA; ZIMBABWE;

EID: 84876283123     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31827f44ee     Document Type: Article

References (28)

1. Six Week Extended-Dose Nevirapine (SWEN) Study Team. Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials. Lancet. 2008;372:300-13
2. Kumwenda NI, Hoover DR, Mofenson LM, et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med. 2008;359:119-129
3. Coovadia HM, Brown ER, Fowler MG, et al.HPTN 046 protocol team. Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial. Lancet. 2012;379:221-228
4. Chasela CS, Hudgens MG, Jamieson DJ, et al.BAN Study Group. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med. 2010;362:2271-2281
5. Kilewo C, Karlsson K, Ngarina M, et al.Mitra Plus Study Team. Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the Mitra Plus study. J Acquir Immune Defic Syndr. 2009;52:406-416
6. Marazzi MC, Nielsen-Saines K, Buonomo E, et al. Increased infant human immunodeficiency virus-type one free survival at one year of age in sub-saharan Africa with maternal use of highly active antiretroviral therapy during breast-feeding. Pediatr Infect Dis J. 2009;28:483-487
7. Taha TE, Kumwenda J, Cole SR, et al. Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy. J Infect Dis. 2009;200:1490-1497
8. Thomas TK, Masaba R, Borkowf CB, et al.KiBS Study Team. Triple-antiretroviral prophylaxis to prevent mother-to-child HIV transmission through breastfeeding-the Kisumu Breastfeeding Study, Kenya: a clinical trial. PLoS Med. 2011;8:e1001015
9. Moorthy A, Kuhn L, Coovadia A, et al. Induction therapy with protease-inhibitors modifies the effect of nevirapine resistance on virologic response to nevirapine-based HAART in children. Clin Infect Dis. 2011;52:514-521
10. Church JD, Omer SB, Guay LA, et al. Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-Dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission. J Infect Dis. 2008;198:1075-1082
11. Moorthy A, Gupta A, Bhosale R, et al. Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants. PLoS ONE. 2009;4:e4096
12. Fogel J, Hoover DR, Sun J, et al. Analysis of nevirapine resistance in HIV-infected infants who received extended nevirapine or nevirapine/zidovudine prophylaxis. AIDS. 2011;25:911-917
13. Fogel J, Li Q, Taha TE, et al. Initiation of antiretroviral treatment in women after delivery can induce multiclass drug resistance in breastfeeding HIV-infected infants. Clin Infect Dis. 2011;52:1069-1076
14. Zeh C, Weidle PJ, Nafisa L, et al. HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis. PLoS Med. 2011;8:e1000430
15. Arrivé E, Newell ML, Ekouevi DK, et al.Ghent Group on HIV in Women and Children. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol. 2007;36:1009-1021
16. Eshleman SH, Jackson JB. Nevirapine resistance after single dose prophylaxis. AIDS Rev. 2002;4:59-63
17. Persaud D, Bedri A, Ziemniak C, et al.Ethiopian Swen Study Team. Slower clearance of nevirapine resistant virus in infants failing extended nevirapine prophylaxis for prevention of mother-to-child HIV transmission. AIDS Res Hum Retroviruses. 2011;27:823-829
18. Lidstrom J, Guay LA, Musoke P, et al. Multi-class drug resistance arises frequently in HIV-infected breastfeeding infants whose mothers initiate highly active antiretroviral therapy (HAART) postpartum. 2010Paper presented at: 17th Conference on Retroviruses and Opportunistic InfectionsSan Francisco, CA Abstract T-124.
19. Mackie N, Dustan S, McClure MO, et al. Detection of HIV-1 antiretroviral resistance from patients with persistently low but detectable viraemia. J Virol Methods. 2004;119:73-78
20. Eshleman SH, Guay LA, Mwatha A, et al. Characterization of nevirapine resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012). J Acquir Immune Defic Syndr. 2004;35:126-130
21. Stanford University. HIV drug resistance database. 2012 Available at: http://hivdb.stanford.edu/. Accessed January 23, 2012
22. Lidström J, Li Q, Hoover DR, et al. Addition of extended zidovudine to extended nevirapine prophylaxis reduces nevirapine resistance in infants who were HIV-infected in utero. AIDS. 2010;24:381-386
23. Mirochnick M, Thomas T, Capparelli E, et al. Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. Antimicrob Agents Chemother. 2009;53:1170-1176
24. Kunz A, Frank M, Mugenyi K, et al. Persistence of nevirapine in breast milk and plasma of mothers and their children after single-dose administration. J Antimicrob Chemother. 2009;63:170-177
25. Coates JA, Cammack N, Jenkinson HJ, et al. (-)-2’-deoxy-3’-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob Agents Chemother. 1992;36:733-739
26. World Health Organization (WHO). Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: towards universal access. 2010 Available at: http://whqlibdoc.who.int/publications/2010/9789241599818_eng.pdf. Accessed: March 12, 2012
27. Palumbo P, Lindsey JC, Hughes MD, et al. Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med. 2010;363:1510-1520
28. World Health Organization (WHO). Antiretroviral therapy for HIV infection in infants and children: towards universal access. Recommendations for a public health approach. 2010 Available at: http://whqlibdoc.who.int/publications/2010/9789241599801_eng.pdf. Accessed December 22, 2011